Actively Recruiting
Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.
Led by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Updated on 2025-09-22
52
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial will evaluate the effectiveness of platelet-rich plasma (PRP) injections for patients with anterior cruciate ligament (ACL) injury. ACL injuries commonly cause knee instability, pain, and reduced function, and rehabilitation alone may not fully restore recovery in all patients. PRP is prepared from a small sample of the patient's own blood and contains natural growth factors that may promote healing and improve joint function. In this study, participants will be randomly assigned to one of two groups. The experimental group will receive a single ultrasound-guided injection of PRP into the knee joint along with a standard rehabilitation program. The control group will receive the rehabilitation program alone. Participants will be followed up at 3 weeks, 8 weeks, and 16 weeks after treatment. At each follow-up visit, knee function, pain level, and physical performance will be assessed using validated outcome measures. The primary aim is to determine whether PRP provides additional benefit compared with rehabilitation alone in improving function and reducing symptoms in ACL-injured patients. This study will provide new evidence about the role of PRP in ACL management, which may help guide future treatment decisions.
CONDITIONS
Official Title
Clinical Outcome of Intra Articular Injection of Autologous Platelet Rich Plasma in Anterior Cruciate Ligament Injury.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of both sexes who are older than 18 years and younger than 50 years
- History of knee injury within the past 3 months or less
- ACL injury MRI Grade 1 (Low) or Grade 2 (Medium)
- ACL injury may be associated with Grade 1 or 2 PCL tear and/or Grade 1 or 2 meniscal tear
- Hemoglobin greater than 10 gm/dl and platelet count greater than 150,000/microliter before procedure
- Able to understand and provide informed consent
You will not qualify if you...
- Received intra articular corticosteroid injections in the injured knee within the last 12 weeks
- Currently taking systemic steroids
- Younger than 18 or older than 50 years
- History of platelet disorders or using anticoagulant or antiplatelet medications
- Hemoglobin below 10 gm/dl
- Platelet count below 150,000/microliter
- Complete tear of both ACL bundles on MRI
- Grade 3 or higher PCL or meniscal tear on MRI
- Previous or current ligament reconstruction in the injured knee
- Connective tissue disorders such as Marfan Syndrome or Ehler-Danlos Syndrome
- Any inflammatory disease affecting the knee such as Rheumatoid Arthritis, spondyloarthritis, gout, or pseudogout
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1000
Actively Recruiting
Research Team
D
Dr. Isfath Fauzia, MBBS
CONTACT
P
Prof. Dr. Md. Ali Emran, MBBS, FCPS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here